News
EBViously Presents Novel In-Vitro Data Demonstrating Potent Infection Prevention of its Vaccine Candidate EBV-001
— Presentation at the World Vaccine Congress West Coast2023
— EBV-001 is designed for the prevention of Epstein-Barr Virus (EBV)-induced diseases via high titers of potent, neutralizing antibodies
— Novel in-vitro data support preclinical proof-of-concept data
EBViously, a start-up developing novel vaccines based on next-generation virus-like particles, has presented new in vitro data of its EBV-vaccine candidate EBV-001 at the World Vaccine Congress West Coast 2023 (Nov. 27-30, 2023) in Santa Clara, CA (USA). The presentation by EBViously’s designated COO Sebastian Goy was held on Thursday, November 30, 2023. Read more…